ARCHIVES

In Brief: Thomas Jordan Promoted At Bristol-Myers, Markison To Succeed Him In Oncology Div.

This article is from The Cancer Letter archive.

Vol. 18 No. 09 | February 28, 1992

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Would Give Clearer Picture Of C225 Role.

February 15, 2002

Feds Should Lead Quality Improvement In Government Health Programs, IOM Report Says

November 8, 2002

Medicare coverage and quality of care top ASCO’s list of policy priorities for 2004.

February 27, 2004

Study Tracks Lifestyle Factors For Cancer Burden In Blacks

October 26, 2001

Amgen Cancels Rilotumumab Trials in Gastric Cancer

December 26, 2014

Auditor Raymond Weiss Finds “Incredible” Protocol Violations–26% Of Patients Were Ineligible For C225 Study

June 21, 2002